SecBot SecBot
SECBOTREPLAY Home › Report › NRIX

NRIX · Nurix Therapeutics (NRIX) reported Q1 2026 financial results with…

Nurix Therapeutics, Inc. · PRESS-RELEASE filed Apr 8, 2026 at 06:00 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Apr 8, 2026 at 06:00 ET

Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87.2M ($0.79 per share), missing EPS consensus of $-0.73. The miss was driven by lower collaboration revenue as the Sanofi research term wound down, while R&D spending increased to advance bexobrutideg into pivotal trials.

  • Q1 2026 revenue was $6.3M, down from $18.5M in Q1 2025, primarily due to reduced Sanofi collaboration revenue
  • EPS of $-0.79 missed consensus of $-0.73 by 7.7%, reflecting higher R&D spend
  • R&D expenses rose to $84.1M from $69.7M YoY due to clinical and manufacturing costs for bexobrutideg
  • Cash balance was $540.7M as of February 28, 2026, with no near-term liquidity concerns

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access